BD PROJECTS

• Product for Licensing

  A Best-in-class potential Lp(a) siRNA for licensing | DrugTimes BD Project

  2026年5月14日
• Bio News

  【DrugTimes Deal】SiranBio and GSK enter license agreement for oligonucleotide candidate targeting metabolic and vascular risk

  2026年5月6日
• PCC

  A Best-in-Class Oral Small-Molecule GLP-1 Receptor Agonist with Superior Weight Loss and Appetite Suppression Efficacy | DrugTimes BD Opportunity

  2025年8月19日
• Product for Licensing

  【SELL】A Highly Potent, Selective, Tissue-Enriched Oral Pan-KRAS (ON & OFF) Inhibitor for licensing

  2025年8月12日
• Insights

  Approaching $6 Billion! XtalPi Secures Major Out-Licensing Agreement

  2025年8月6日
• Insights

  Failure Against Placebo? Vertex Stumbles in Pursuit of Billion-Dollar Non-Opioid Analgesia Market

  2025年8月6日
• Insights

  Has the mRNA Vaccine Era Collapsed? Kennedy Announces Cancellation of Funding for 22 mRNA Vaccine Projects

  2025年8月6日
• Insights

  Patient Death in Trial Marks Setback for Allogene’s Off-the-shelf CAR-T

  2025年8月5日
• Insights

  CellOrigin’s DLL3 CAR-T Accepted by CDE, China Leads Global DLL3 Therapeutic Development

  2025年8月5日
• Insights

  Q2 Loss of $800 Million, 10% Workforce Reduction, CEO Rejects M&A Deal

  2025年8月5日